This protocol details antiviral screening against dengue, highlighting activity via IC50 values and cytotoxicity assessments.
The following is a protocol for live virus antiviral screening against Dengue in vitro. Cells are prophylactically treated with antiviral candidates that have been serially diluted to investigate activity, via IC50 values generated via analysis of immunofluorescent staining, against Dengue. You may omit PgP inhibtior. Each live virus screening assay is accompanied by a matching cytotoxicity screening assay to investigate drug toxicity.
No takes yet. Share an insight, caveat, or question.
Briana L McGovern (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: